Ideal Taxes Association

Raymond Richman       -       Jesse Richman       -       Howard Richman

 Richmans' Trade and Taxes Blog



Zinc: The Missing Element in the HCQ/COVID-19 Debate - I'm published in the American Thinker blog this morning
Howard Richman, 4/26/2020

Here's a selection:

On April 21, Dr. Fauci’s National Institute of Allergy and Infectious Diseases (NIAID) recommended against using the combination of HCQ and azithromycin for treating COVID-19 due to irregular heartbeats that can result. It based its recommendation upon a VA hospital retrospective study conducted without using zinc upon patients who were probably zinc-deficient, being elderly and about 2/3 Black.

In that study, the patients in the HCQ groups died at a significantly higher rate than the patients who had not received HCQ. But the higher death rate in the HCQ groups may have been due to the fact that the VA put sicker patients into the two groups taking HCQ (one of which also took azithromycin), while putting healthier patients into the control group that didn’t take HCQ. The GoodRX blog noticed this flaw. They wrote:...

One thing to note is that people who had more severe symptoms, which might partially explain the higher death rates, were also more likely to get medications...."

Even worse, Fauci’s NIAID never even considered the fact that the VA was treating a group that is known to be zinc deficient without adding zinc supplements. Nor did they consider the interaction between HCQ and zinc, such that HCQ either works better if combined with zinc, or HCQ can deprive patients of needed zinc if not administered along with zinc supplements to zinc-deficient patients.

Click here to read it on the American Thinker website.

 

 

Read more...

Comments: 3


Fauci time and the Coronavirus Vaccine - I'm published in American Thinker
Howard Richman, 4/17/2020

The American vaccine’s Phase 1 clinical trials are bogged down. They began on March 3 and are not scheduled to end until June 1, 2021.

Why fifteen months for the first American vaccine’s clinical trials? The reason is simple. Dr. Anthony Fauci, the director of NIAID (National Institute of Allergy and Infectious Diseases), is conducting them in Fauci Time.  (Fauci is also conducting the clinical trials to see if Remdesivir is effective against COVID-19 in Fauci Time – those trials are not scheduled to end until April 1, 2023.)

Normally, during a health emergency, the U.S. gets out a vaccine within months. Take the H1N1 (Swine Flu) pandemic of 2009. The CDC has published a timeline:

  • April 15. First human infection.
  • May 5. School closings affect 607,778 students.
  • July 22. Clinical trials begin.
  • September 15. Four vaccines approved.

So, in 2009, the FDA started its clinical trials of a vaccine on July 22 and approved four vaccines seven weeks later. Meanwhile, in 2019, Fauci’s NIAID started its clinical trials on March 3 and plans to take 15 months to complete them.

U.S. regulations allow for two rapid approval processes for vaccines during a health emergency. One of them, called Accelerated Approval, is the process used to approve the H1N1 vaccines after less than two months of clinical trials. The other, called Emergency Use Authorization, is the process used to approve the anthrax vaccine so that it could be administered to the soldiers invading Iraq.

In the Accelerated Approval process, a single clinical trial phase determines whether the vaccine is safe and whether it creates the required antibodies. In vaccine terminology, these pathogen-specific antibodies are considered to be a “surrogate endpoint,” permitting the vaccine to be approved for use without field studies. For such vaccines, there is a “Phase 4” process during which the success of the vaccine is continuously monitored while it is being used.

The following are among the successful vaccines approved through the Accelerated Approval process:...

Click here to read it on the American Thinker website

 

Read more...

Comments: 0


Testing Hydroxychloroquine as a Prophylactic -- I'm published in this morning's American Thinker
Howard Richman, 4/13/2020

There are three experiments getting started now that will determine whether hydroxychloroquine (HCQ) works as a prophylactic. A prophylactic functions almost like a vaccine, except that it has to be taken daily.

All three experiments are the type that researchers dream about. They are called double-blind studies because neither the subjects nor the people working with the subjects will know which subjects are taking an HCQ pill and which are taking a placebo pill. Both pills will look identical.

The subjects of all three experiments will be healthcare workers and/or first responders. The experimenters will follow the subjects closely to determine which ones catch COVID-19. All three experiments are being conducted by reputable top-notch institutions:...

To read it on the American Thinker website, go to:

https://www.americanthinker.com/blog/2020/04/testing_hydroxychloroquine_as_a_prophylactic.html

Read more...

Comments: 0


State restrictions on the use of HCQ
Howard Richman, 4/12/2020

I've gone through two websites (one published by the National Academy for State Health Policy and the other published by the American Medical Association) and have classified state restrictions regarding use of HCQ (hydroxychloroquine) to treat COVID-19.  I have classified those state policies into three groups:

  1. Legal Restrictions: IL, MI, MS, NY, OH, and OR.
  2. Pharmacy Discretion: KS , KY, LA, and SC.
  3. Not for Prophylaxis:  IA, ID, MO, NJ, NV, NC, RI TX and WI.

Others may look at the same charts and classify the states differently. The rules regarding Pharmacy Discretion and Prophylaxis are largely to prevent shortages from occurring in the event that there is not enough to go around.  The Legal Restrictions appear to be designed to prevent primary care physicians from prescribing HCQ based upon symptoms. In this posting, I will just discuss the states that have legal restrictions:

  • IL. Only those with a positive test result for COVID-19 may get a prescription.
  • MI. Those who prescribe HCQ or fill HCQ prescriptions without further proof of efficacy for treating COVID-19 may be investigated and lose their licence.
  • MS. Prescriptions limited to those who have been admitted to hospitals.
  • NY. Prescriptions are limited to those who have tested positive.
  • OH. Prescriptions are limited to those who have tested positive.
  • OR. Prescriptions are limited to those who have tested positive or have a clinical diagnosis.

And here's a table showing the deaths per case and deaths per million people in the states with legal restrictions, as compared to the national average of all 50 states:...

Read more...

Comments: 2


Lots of studies of HCQ - none of which use zinc
Howard Richman, 4/12/2020

We will soon know whether HCQ (hydroxychloroquine) works by itself (none include zinc with the HCQ). I just searched clinicaltrials.gov. Eight new studies are testing the effectiveness of HCQ against COVID-19:

  1. Henry Ford Health System. Healthcare workers and first responders will take either HCQ or a placebo as a prophylactic.
  2. Pastier Institute in France. Healthcare workers will take either HCQ or placebo as a phophylactic.
  3. Duke University. Healthcare workers will get HCQ or placebo as a prophylactic.
  4. Gangnam Severance Hospital, South Korea. Those who have been exposed to COVID-19 will get HCQ, others will get no intervention.
  5. Rambam Health Care in Israel. Those with mild to moderate COVID-19 will get HCQ.
  6. Azidus Brazil.  Those who have moderate to severe pneumonia as an after effect of COVID-19 will get HCQ and an antibiotic.
  7. University of Calgary. HCQ or placebo will be given to patients within 96 hours of a positive COVID-19 result.
  8. Instituto de Investigacion Marques de Valdecilla Spain. Patients with COVID 19 will be compared to patients with Immuno-mediated Inflammatory Disease as far as their response to HCQ is concerned....

 

Read more...

Comments: 0


Deborah Birx: 1 million Abbott Lab tests not being used.
Howard Richman, 4/10/2020

See this video from Wednesday's Coronavirus task force briefing at the 1:38:35 mark:

Read more...

Comments: 0


Detroit hospital system starts test of HCQ as Prophylactic
Howard Richman, 4/9/2020

President Trump isn't the only one who is bypassing the Washington bureaucracy in an attempt to find a solution to COVID-19. The Henry Ford Health System in Detroit has announced the WHIP COVID-19 study to find out whether HCQ (hydroxychloroquine) works as a prophylactic. They are now asking for volunteers among healthcare workers and first responders, people who are likely to come into contact with those who are sick from the virus. It will be a randomized, double blinded study, and the first results will become available about 4 weeks after the experiment begins -- probably around June 1. 

They started the study in response to a request from Detroit's mayor and local health care experts, according to their April 2 press release:...

Read more...

Comments: 0


Fauci now is part of the problem, not part of the solution - I'm published in April 8 American thinker blog
Howard Richman, 4/7/2020

The South Korean solution to the COVID-19 virus (widespread testing and the hydroychloroquine-zinc cure) is beginning to work in the United States. Americans, like South Koreans, will soon be back at work and school. But at Monday's Coronavirus Task Force press briefing, Dr. Anthony Fauci ignored the success. Instead, he pretended that the only way the U.S. could get back to normal was through vaccines and new therapies. He was responding to a question directed to him by reporter Jonathan Karl at the 37:37 mark of this video:

Karl: Will we truly get back to normal before there’s a vaccine available to everybody?...

Fauci: … I believe with the therapies that will be coming online, with the fact that I feel confident that over a period of time we will get a good vaccine, that we will never have to get back to where we are right now. So, if that means getting back to normal, then we’ll get back to normal.

Fauci was being disingenuous. His own organization NIAID (one of the institutes of NIH) is slow-walking both therapies and vaccines. For example, NIAID is currently conducting a study on the effectiveness of Remdesivir, a drug which, along with chloroquine and hydroxychloroquine, proved effective against COVID-19 in the Chinese test-tube studies. Here's NIAID's schedule for completing Phase 3 of its approval process:

  • Actual Study Start Date: February 2, 2020
  • Estimated Primary Completion Date: April 1, 2023
  • Estimated Study Completion Date: April 1, 2023

Believe it or not, that is not a misprint! Fauci was touting new therapies even while his own organization was slow walking the most promising of them so that it would not be ready until 2023! 

The same is true of vaccines....

[Click here to read it on the American Thinker website.]

Read more...

Comments: 1


The solution to COVID-19 is in Sight! - we're published in today's American Thinker
Howard Richman, 4/6/2020

The solution to COVID-19 is in Sight! It is the South Korean solution: (1) widespread testing, and (2) treatment at home using a hydroxychloroquine-zinc cocktail.

The South Korea solution works! People there are back at work. The death ratios (deaths/recoveries; deaths/cases) are low. Unfortunately, the bureaucrats in the U.S. health bureaucracy are trying to stop it from happening in the United States. See the commentary that my son and I wrote in today’s American Thinker:

https://www.americanthinker.com/articles/2020/04/a_solution_to_covid19_is_in_sight.html

 

Read more...

Comments: 0





  • Richmans' Blog    RSS
  • Our New Book - Balanced Trade
  • Buy Trading Away Our Future
  • Read Trading Away Our Future
  • Richmans' Commentaries
  • ITA Working Papers
  • ITA on Facebook
  • Contact Us

    Archive
    Jul 2020
    Jun 2020
    May 2020
    Apr 2020

    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013
    October 2013
    September 2013
    August 2013
    July 2013
    June 2013
    May 2013
    April 2013
    March 2013
    February 2013
    January 2013
    December 2012
    November 2012
    October 2012
    September 2012
    August 2012
    July 2012
    June 2012
    May 2012
    April 2012
    March 2012
    February 2012
    January 2012
    December 2011
    November 2011
    October 2011
    September 2011
    August 2011
    July 2011
    June 2011
    May 2011
    April 2011
    March 2011
    February 2011
    January 2011
    December 2010
    November 2010
    October 2010
    September 2010
    August 2010
    July 2010
    June 2010
    May 2010
    April 2010
    March 2010
    February 2010
    January 2010

    Categories:
    Book Reviews
    Capital Gains Taxation
    Corporate Income Tax
    Consumption Taxes
    Economy - Long Term
    Economy - Short Term
    Environmental Regulation
    Politics
    Real Estate Taxation
    Trade
    Miscellaneous

    Outside Links:

  • American Economic Alert
  • American Jobs Alliance
  • Angry Bear Blog
  • Economy in Crisis
  • Econbrowser
  • Emmanuel Goldstein's Blog
  • Levy Economics Institute
  • McKeever Institute
  • Michael Pettis Blog
  • Naked Capitalism
  • Natural Born Conservative
  • Science & Public Policy Inst.
  • TradeReform.org
  • Votersway Blog
  • Watt's Up With That


    Wikipedia:

  • [An] extensive argument for balanced trade, and a program to achieve balanced trade is presented in Trading Away Our Future, by Raymond Richman, Howard Richman and Jesse Richman. “A minimum standard for ensuring that trade does benefit all is that trade should be relatively in balance.” [Balanced Trade entry]

    Journal of Economic Literature:

  • [Trading Away Our Future] Examines the costs and benefits of U.S. trade and tax policies. Discusses why trade deficits matter; root of the trade deficit; the “ostrich” and “eagles” attitudes; how to balance trade; taxation of capital gains; the real estate tax; the corporate income tax; solving the low savings problem; how to protect one’s assets; and a program for a strong America....

    Atlantic Economic Journal:

  • In Trading Away Our Future   Richman ... advocates the immediate adoption of a set of public policy proposal designed to reduce the trade deficit and increase domestic savings.... the set of public policy proposals is a wake-up call... [February 17, 2009 review by T.H. Cate]